drugset / Trial / NCT01429051
A Clinical Trial With Intranasal Fentanyl in Cancer Patients With Breakthrough Pain
NaSingle-groupDouble-blindTreatment
Summary
The aim of this clinical trial was to demonstrate the efficacy of a 400 μg dose strength of intranasal fentanyl spray (INFS, Instanyl®) and to evaluate the safety and to establish long term tolerability of treatment with INFS doses of 50, 100, 200 and 400 μg.
Timeline
- Start
- 2011-08
- Primary completion
- 2013-01
- Completion
- 2013-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fentanyl | Other / unclassified | 50 ug | Intranasal |
| Subject | Fentanyl | Other / unclassified | 100 ug | Intranasal |
| Subject | Fentanyl | Other / unclassified | 200 ug | Intranasal |
| Subject | Fentanyl | Other / unclassified | 400 ug | Intranasal |